Anne Munck1, Corinne Alberti2, Carla Colombo3, Nataliya Kashirskaya4, Helmut Ellemunter5, Maria Fotoulaki6, Roderick Houwen7, Eddy Robberecht8, Priscilla Boizeau9, Michael Wilschanski10. 1. Hôpital Robert Debré, Paediatric Gastroenterology and Respiratory Department, CF Centre, University Paris 7, 75019 Paris, France. Electronic address: anne.munck@rdb.aphp.fr. 2. Hôpital Robert Debré, Clinical Epidemiology Unit, 75019 Paris, France; Sorbonne Paris Cité, UMR-S1123, ECEVE, University Paris Diderot, 75019 Paris, France; Inserm U1123 and CIC-EC 1426, 75019 Paris, France. 3. Fondazione IRCCS Ca'Granda, Ospedale Maggiore Policlinico, University of Milan, Milan, Italy. 4. Federal State Budgetary Institution "Research Centre for Medical Genetics", Moscow, Russian Federation. 5. Medical University, Innsbruck, Austria. 6. University of Thessaloniki, Thessaloniki, Greece. 7. Wilhelmina Children's Hospital, University Medical Centre, Utrecht, the Netherlands. 8. University Hospital, Ghent, Belgium. 9. Hôpital Robert Debré, Clinical Epidemiology Unit, 75019 Paris, France. 10. Hadassah Hebrew University Medical Centre, Jerusalem, Israel.
Abstract
BACKGROUND: Distal intestinal obstruction syndrome (DIOS) is a specific complication of cystic fibrosis. METHODS: A study was performed in 10 countries to prospectively evaluate the incidence, associated factors, and treatment modalities in children and adults. RESULTS: 102 patients presented 112 episodes. The incidence of DIOS was similar in children and adults. Medical treatment failed only in cases of complete DIOS (11%). Children with meconium ileus had a higher rate of surgery for DIOS (15% vs. 2%, p=0.02). Complete DIOS entailed longer hospitalisation (4 [3; 7] days vs. 3 [1; 4], p=0.002). Delayed arrival at hospital and prior weight loss had a significant impact on the time needed for DIOS resolution. Associated CF co-morbidities for DIOS included meconium ileus (40% vs. 18%, p<0.0001), exocrine pancreatic insufficiency (92% vs. 84%, p=0.03), liver disease (22% vs. 12%, p=0.004), diabetes mellitus (49% vs. 25%, p=0.0003), and Pseudomonas aeruginosa (68% vs. 52%, p=0.01); low fibre intake and insufficient hydration were frequently observed. Female gender was associated with recurrent DIOS (75% vs. 52%, p=0.04), constipation with incomplete episodes (39% vs. 11%, p=0.03), and poor patient compliance in taking pancreatic enzyme therapy during complete episodes (25% vs. 3%, p=0.02). CONCLUSION: DIOS is a multifactorial condition having a similar incidence in children and adults. We show that delayed arrival at hospital after the initial symptoms causes significant morbidity. Early recognition and treatment would improve the prognosis.
BACKGROUND: Distal intestinal obstruction syndrome (DIOS) is a specific complication of cystic fibrosis. METHODS: A study was performed in 10 countries to prospectively evaluate the incidence, associated factors, and treatment modalities in children and adults. RESULTS: 102 patients presented 112 episodes. The incidence of DIOS was similar in children and adults. Medical treatment failed only in cases of complete DIOS (11%). Children with meconium ileus had a higher rate of surgery for DIOS (15% vs. 2%, p=0.02). Complete DIOS entailed longer hospitalisation (4 [3; 7] days vs. 3 [1; 4], p=0.002). Delayed arrival at hospital and prior weight loss had a significant impact on the time needed for DIOS resolution. Associated CF co-morbidities for DIOS included meconium ileus (40% vs. 18%, p<0.0001), exocrine pancreatic insufficiency (92% vs. 84%, p=0.03), liver disease (22% vs. 12%, p=0.004), diabetes mellitus (49% vs. 25%, p=0.0003), and Pseudomonas aeruginosa (68% vs. 52%, p=0.01); low fibre intake and insufficient hydration were frequently observed. Female gender was associated with recurrent DIOS (75% vs. 52%, p=0.04), constipation with incomplete episodes (39% vs. 11%, p=0.03), and poor patient compliance in taking pancreatic enzyme therapy during complete episodes (25% vs. 3%, p=0.02). CONCLUSION: DIOS is a multifactorial condition having a similar incidence in children and adults. We show that delayed arrival at hospital after the initial symptoms causes significant morbidity. Early recognition and treatment would improve the prognosis.
Authors: Carlos Antonio Morales Morales; Mauricio Gonzalez-Urquijo; Luis Fernando Morales Flores; Enrique Quevedo-Fernandez; Eduardo Alberto Guzmán Huerta; Martín Mauricio Virgilio Hernández-Torre Journal: Ann Med Surg (Lond) Date: 2020-12-03
Authors: Ana Luiza Melo Dos Santos; Helen de Melo Santos; Marina Bettiol Nogueira; Hugo Tadashi Oshiro Távora; Maria de Lourdes Jaborandy Paim da Cunha; Renata Belém Pessoa de Melo Seixas; Luciana de Freitas Velloso Monte; Elisa de Carvalho Journal: Pediatr Gastroenterol Hepatol Nutr Date: 2018-10-10
Authors: Natascha S Sandy; Lilian H P Massabki; Aline C Gonçalves; Antonio F Ribeiro; Jose D Ribeiro; Maria de Fátima C P Servidoni; Elizete A Lomazi Journal: J Pediatr (Rio J) Date: 2019-10-22 Impact factor: 2.990